FDA panel backs Novavax vaccine, citing need for another technology

A week after FDA’s briefing document linked Novavax’s COVID-19 vaccine to myocarditis and four months after the company’s much delayed EUA submission, Novavax took a step closer to authorization with the agency’s vaccine advisory committee voting nearly unanimously in favor of the candidate. 

Developed in collaboration with the Coalition for Epidemic Preparedness Innovations and partially funded by Operation Warp Speed, NVX-CoV2373, also known as Covovax, is a recombinant protein nanoparticle vaccine against a full-length, prefusion-stabilized version of the SARS-CoV-2 spike protein, delivered in combination with the company’s saponin-based Matrix-M adjuvant. ...